Israel - English - Ministry of Health

astrazeneca (israel) ltd - durvalumab - solution for infusion - durvalumab 50 mg/ml - durvalumab - urothelial carcinoma imfinzi is indicated for the treatment of patients with pd-l1 high (tumor cell ≥25% or ic ≥25%) locally advanced or metastatic urothelial carcinoma who: - have disease progression during or following platinum-containing chemotherapy. - have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. non-small cell lung cancer - imfinzi is indicated for the treatment of patients with unresectable stage iii non-small cell lung cancer (nsclc) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.- imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations.small cell lung cancer imfinzi, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc).biliary tract cancersimfinzi in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (btc).hepatocellular carcinomaimfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Israel - English - Ministry of Health

astrazeneca (israel) ltd - durvalumab - solution for infusion - durvalumab 50 mg/ml - durvalumab - urothelial carcinoma imfinzi is indicated for the treatment of patients with pd-l1 high (tumor cell ≥25% or ic ≥25%) locally advanced or metastatic urothelial carcinoma who: - have disease progression during or following platinum-containing chemotherapy. - have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy. non-small cell lung cancer - imfinzi is indicated for the treatment of patients with unresectable stage iii non-small cell lung cancer (nsclc) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.- imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations.small cell lung cancer imfinzi, in combination with etoposide and either carboplatin or cisplatin, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc).biliary tract cancersimfinzi in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (btc).hepatocellular carcinomaimfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - mometasone furoate - lotion - mometasone furoate 1 mg/g - mometasone - mometasone - the relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses, such as psoriasis and atopic dermatitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - mometasone furoate - lotion - mometasone furoate 1 mg/g - mometasone - mometasone - the relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses, such as psoriasis and atopic dermatitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - mometasone furoate - cream - mometasone furoate 0.1 % - mometasone - mometasone - for the relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses such as psoriasis and atopic dermatitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - mometasone furoate - ointment - mometasone furoate 0.1 % - mometasone - mometasone - for the relief of the inflammatory and pruritic manifestations of corticosteroid - responsive dermatoses such as psoriasis and atopic dermatitis.

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - fluvoxamine maleate - tablets - fluvoxamine maleate 100 mg - fluvoxamine - fluvoxamine - for the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. treatment of obsessive compulsive disorders (ocd).

Israel - English - Ministry of Health

padagis israel pharmaceuticals ltd, israel - fluvoxamine maleate - tablets - fluvoxamine maleate 50 mg - fluvoxamine - fluvoxamine - for the treatment of affective disorders characterized by persistent low mood, impaired psychomotor atctivities and psychomatic complaints including symptoms of depression. treatment of obsessive compulsive disorders (ocd).

Israel - English - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera, a combination of two nucleoside analog hiv 1 reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (rilpivirine), is indicated for use as a complete regimen for the treatment of hiv-1 infection in adult patients with no antiretroviral treatment history and with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy, and in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below).the following points should be considered when initiating therapy with eviplera in adult patients with no antiretroviral treatment history: • more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared to rilpivirine-treated subjects with hiv-1 rna less than or equal to 100,000 copies/ml [see clinical studies (14)]. • regardless of hiv-1 rna level at the start of therapy, more rilpivirine-treated subjects with cd4+ cell count less than 200 cells/mm3 experienced virologic failure compared to rilpivirine-treated subjects with cd4+ cell count greater than or equal to 200 cells/mm3 [see clinical studies (14)]. • the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz [see microbiology (12.4)]• more subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [see microbiology (12.4)].

Israel - English - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera, a combination of two nucleoside analog hiv 1 reverse transcriptase inhibitors (emtricitabine and tenofovir disoproxil fumarate) and one non-nucleoside reverse transcriptase inhibitor (rilpivirine), is indicated for use as a complete regimen for the treatment of hiv-1 infection in adult patients with no antiretroviral treatment history and with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy, and in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see below).the following points should be considered when initiating therapy with eviplera in adult patients with no antiretroviral treatment history: • more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure (hiv-1 rna ≥50 copies/ml) compared to rilpivirine-treated subjects with hiv-1 rna less than or equal to 100,000 copies/ml [see clinical studies (14)]. • regardless of hiv-1 rna level at the start of therapy, more rilpivirine-treated subjects with cd4+ cell count less than 200 cells/mm3 experienced virologic failure compared to rilpivirine-treated subjects with cd4+ cell count greater than or equal to 200 cells/mm3 [see clinical studies (14)]. • the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz [see microbiology (12.4)]• more subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [see microbiology (12.4)].